|
GIGYF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.41170474888509E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.2246000042081E-08 |
| Normal-vs-Stage2 |
8.34590000000635E-05 |
| Normal-vs-Stage3 |
6.8936001351716E-10 |
| Normal-vs-Stage4 |
1.01190000822982E-09 |
| Stage1-vs-Stage2 |
9.945200E-01 |
| Stage1-vs-Stage3 |
1.164180E-01 |
| Stage1-vs-Stage4 |
1.907560E-02 |
| Stage2-vs-Stage3 |
2.941800E-01 |
| Stage2-vs-Stage4 |
1.317850E-01 |
| Stage3-vs-Stage4 |
4.765600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.51080037369411E-10 |
| Normal-vs-AfricanAmerican |
3.222600E-03 |
| Normal-vs-Asian |
1.84723999999692E-05 |
| Caucasian-vs-AfricanAmerican |
2.857400E-01 |
| Caucasian-vs-Asian |
6.669800E-01 |
| AfricanAmerican-vs-Asian |
4.971000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.82804940260939E-12 |
| Normal-vs-Female |
5.98619998015693E-09 |
| Male-vs-Female |
3.357700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.31259999980315E-07 |
| Normal-vs-Age(41-60Yrs) |
6.27759999538569E-09 |
| Normal-vs-Age(61-80Yrs) |
8.1782003391595E-10 |
| Normal-vs-Age(81-100Yrs) |
1.775640E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.114200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.659380E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.061610E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.052000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.839190E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.096800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.977600E-02 |
| Classical-VS-Follicular |
6.903700E-02 |
| Classical-VS-Other |
1.066170E-01 |
| Classical-VS-Normal |
1.94050000512647E-08 |
| Tall-VS-Follicular |
5.146200E-01 |
| Tall-VS-Other |
4.745400E-01 |
| Tall-VS-Normal |
4.19110000038359E-07 |
| Follicular-VS-Other |
3.864800E-01 |
| Follicular-VS-Normal |
6.57559999783786E-08 |
| Other-VS-Normal |
8.759600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.53459997434646E-09 |
| Normal-vs-N1 |
8.05430000472285E-08 |
| N0-vs-N1 |
2.958600E-01 |
|
|
